The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation

J Immunol. 1999 Apr 15;162(8):4472-81.

Abstract

IL-12 and IL-2 can stimulate mitogen- or CD3-activated T cells to proliferate, produce IFN-gamma, and kill tumor cells. The magnitude of these functional responses is greatly augmented when T cells are activated by the combination of IL-12 and IL-2. Although peripheral blood T cells are largely unresponsive to these cytokines without prior activation, a small subset of CD8+ T cells (CD8+CD18bright) is strongly activated by the combination of IL-12 and IL-2. In this report we show that the functional synergy between IL-12 and IL-2 in CD8+CD18bright T cells correlates with the activation of the stress kinases, p38 mitogen-activated protein (MAP) kinase and stress-activated protein kinase (SAPK)/Jun N-terminal kinase, but not with the activation of the extracellular signal-regulated kinases. The functional synergy between IL-2 and IL-12 is also associated with a prominent increase in STAT1 and STAT3 serine phosphorylation over that observed with IL-12 or IL-2 alone. By contrast, STAT tyrosine phosphorylation is not augmented over that seen with either cytokine alone. A specific inhibitor of p38 MAP kinase completely inhibits the serine phosphorylation of STAT1 and STAT3 induced by IL-12 and IL-2 and abrogates the functional synergy between IL-12 and IL-2 without affecting STAT tyrosine phosphorylation. This suggests that p38 MAP kinase may play an important role in regulating STAT serine phosphorylation in response to the combination of IL-12 and IL-2. Furthermore, these findings indicate that the optimal activation of T cells by IL-12 and IL-2 may depend on an interaction between the p38 MAP kinase and Janus kinase/STAT signaling pathways.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adjuvants, Immunologic / physiology*
  • Animals
  • CD18 Antigens / blood
  • CD8 Antigens / blood
  • Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinases / physiology*
  • DNA-Binding Proteins / metabolism*
  • Drug Synergism
  • Enzyme Activation / immunology
  • Humans
  • Imidazoles / pharmacology
  • Interleukin-12 / physiology*
  • Interleukin-2 / physiology*
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinase 1*
  • Mice
  • Mitogen-Activated Protein Kinases*
  • Phosphorylation
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Pyridines / pharmacology
  • STAT1 Transcription Factor
  • STAT3 Transcription Factor
  • Serine / metabolism*
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / enzymology
  • T-Lymphocyte Subsets / immunology
  • Trans-Activators / metabolism*
  • Tyrosine / metabolism
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Adjuvants, Immunologic
  • CD18 Antigens
  • CD8 Antigens
  • DNA-Binding Proteins
  • Imidazoles
  • Interleukin-2
  • Pyridines
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Stat1 protein, mouse
  • Stat3 protein, mouse
  • Trans-Activators
  • Interleukin-12
  • Tyrosine
  • Serine
  • Protein Serine-Threonine Kinases
  • Calcium-Calmodulin-Dependent Protein Kinases
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinase 1
  • MAP3K1 protein, human
  • Map3k1 protein, mouse
  • SB 203580